Bio-Rad Signs a Co-Marketing Agreement with Bruker to Offer a Complete Workflow for Foodborne Pathogen Detection

Date: 
2018-06-20

HERCULES, Calif.–June 20, 2018–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has signed a co-marketing agreement with Bruker to bring foodborne pathogen detection and confirmation workflow solutions to the food safety industry.

Bio-Rad and Bruker each develop, manufacture, and sell products and analytical instruments that are used in food microbiology laboratories. These products and instruments are typically used together by labs in a common workflow of analysis using high performance RAPID’chromogenic media from Bio-Rad to screen food products for the presence of pathogenic bacteria, followed by confirmation and identification of the organism using the MALDI Biotyper® from Bruker.

Several Bio-Rad and Bruker workflows have recently been validated according to the international ISO16140 standard and the workflow for the confirmation and identification step has also received approval by AOAC INTERNATIONAL as an Official Method of Analysis (OMA 2017.09 and OMA 2017.10), demonstrating the accurate and robust performance. Such detection and confirmation methods have been validated for Salmonella spp., Cronobacter spp., Listeria spp., and L. monocytogenes. The MALDI Biotyper simplifies and shortens the confirmation and identification step, facilitating and harmonizing the workflow with only one system.

“We welcome the opportunity to work with Bruker and believe their products and solutions complement Bio-Rad’s existing food safety testing product line,” said Jean-François Chauvet, Bio-Rad Vice President and General Manager, Food Science Division. “The combination of our RAPID’chromogenic media with the MALDI Biotyper will provide an innovative food safety workflow to help protect the food supply.”

“Early adaptors of the MALDI Biotyper are already reporting the benefits of combining chromogenic media with the MALDI Biotyper, increasing their confidence by implementing AOAC OMA and ISO 16140 approved workflows,” added Dr. Daniele Sohier, Business Development Manager for Industrial Microbiology at Bruker. “We are optimistic about achieving this breakthrough in laboratory daily work with Bio-Rad’s range of food safety solutions”.

For more information on Bio-Rad’s complete range of RAPID’chromogenic media, please visit www.bio-rad.com/rapidmedia

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com